Literature DB >> 10750558

Cytoskeletal abnormalities in chondrocytes with EXT1 and EXT2 mutations.

M A Bernard1, D A Hogue, W G Cole, T Sanford, M B Snuggs, D Montufar-Solis, P J Duke, D D Carson, A Scott, W B Van Winkle, J T Hecht.   

Abstract

The EXT genes are a group of putative tumor suppressor genes that previously have been shown to participate in the development of hereditary multiple exostoses (HME), HME-associated and isolated chondrosarcomas. Two HME disease genes, EXT1 and EXT2, have been identified and are expressed ubiquitously. However, the only known effect of mutations in the EXT genes is on chondrocyte function as evidenced by aberrant proliferation of chondrocytes leading to formation of bony, cartilage-capped projections (exostoses). In this study, we have characterized exostosis chondrocytes from three patients with HME (one with EXT1 and two with EXT2 germline mutations) and from one individual with a non-HME, isolated exostosis. At the light microscopic level, exostosis chondrocytes have a stellate appearance with elongated inclusions in the cytoplasm. Confocal and immunofluorescence of in vitro and in vivo chondrocytes showed that these massive accumulations are composed of actin bundled by 1.5-microm repeat cross-bridges of alpha-actinin. Western blot analysis shows that exostosis chondrocytes from two out of three patients aberrantly produce high levels of muscle-specific alpha-actin, whereas beta-actin levels are similar to normal chondrocytes. These findings suggest that mutations in the EXT genes cause abnormal processing of cytoskeleton proteins in chondrocytes.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2000        PMID: 10750558     DOI: 10.1359/jbmr.2000.15.3.442

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  8 in total

Review 1.  The link between heparan sulfate and hereditary bone disease: finding a function for the EXT family of putative tumor suppressor proteins.

Authors:  G Duncan; C McCormick; F Tufaro
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Perlecan-stimulated nodules undergo chondrogenic maturation in response to rhBMP-2 treatment in vitro.

Authors:  Ronald R Gomes; Mary C Farach Carson; Daniel D Carson
Journal:  Connect Tissue Res       Date:  2003       Impact factor: 3.417

3.  Spatiotemporal distribution of heparan sulfate epitopes during murine cartilage growth plate development.

Authors:  Ronald R Gomes; Toin H Van Kuppevelt; Mary C Farach-Carson; Daniel D Carson
Journal:  Histochem Cell Biol       Date:  2006-07-12       Impact factor: 4.304

4.  No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas.

Authors:  Christianne M A Reijnders; Cathelijn J F Waaijer; Andrew Hamilton; Emilie P Buddingh; Sander P D Dijkstra; John Ham; Egbert Bakker; Karoly Szuhai; Marcel Karperien; Pancras C W Hogendoorn; Sally E Stringer; Judith V M G Bovée
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

5.  Etiological point mutations in the hereditary multiple exostoses gene EXT1: a functional analysis of heparan sulfate polymerase activity.

Authors:  P K Cheung; C McCormick; B E Crawford; J D Esko; F Tufaro; G Duncan
Journal:  Am J Hum Genet       Date:  2001-06-05       Impact factor: 11.025

6.  High quality RNA isolation from tumours with low cellularity and high extracellular matrix component for cDNA microarrays: application to chondrosarcoma.

Authors:  H J Baelde; A M Cleton-Jansen; H van Beerendonk; M Namba; J V Bovée; P C Hogendoorn
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

7.  Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I.

Authors:  Margaret M French; Ronald R Gomes; Rupert Timpl; Magnus Höök; Kirk Czymmek; Mary C Farach-Carson; Daniel D Carson
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

8.  Perlecan: an important component of the cartilage pericellular matrix.

Authors:  R Gomes; C Kirn-Safran; M C Farach-Carson; D D Carson
Journal:  J Musculoskelet Neuronal Interact       Date:  2002-12       Impact factor: 2.041

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.